By continuing to use this website, you agree to the use of cookies described in our Cookies Policy. OK Read about our COVID-19 Response. Site Search Page Not Found Site Map We're sorry, but there is no page on the site that matches your entry. It is possible you typed the address incorrectly, or the page may no longer exist. You may wish to try another entry or choose from the links below, which we hope will help you find what you are looking for. If you believe that this page should exist, please send an email to support@q4inc.com explaining the page you were trying to access. Thanks for your patience, understanding, and help. INVESTOR OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS ANNUAL MEETING EVENTS & WEBCASTS FINANCIAL INFORMATION SEC FILINGS ANNUAL REPORTS STOCK INFORMATION ANALYST COVERAGE GOVERNANCE CORPORATE GOVERNANCE RESOURCES EMAIL SUBSCRIPTION INVESTOR CONTACTS Global Headquarters 1220 Concord Avenue Concord, CA US 94520 +1 925.288.6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 Cookie Policy and Tracking Opt-out Guide Legal Privacy Policy Copyright (c) 2021 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. InterSol and Amicus are trademarks of Fenwal, Inc. Back to top About Cerus Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. Powered By Q4 Inc. 5.56.0.1 (opens in new window) About Cerus